SecBot SecBot
Biotech Drug Report Generated Nov 6, 2026

dazucorilant

CORT·CORCEPT THERAPEUTICS INC
MIXED
Drug Impact Rating3/10
Trial phase
Phase 2 (completed)
Time to market
Phase 3 has not yet begun (planned for 2027). If Phase 3 succeeds, potential FDA submission would be several years away, likely 2029-2030 at the earliest.
Why 3/10
Dazucorilant is a Phase 2-stage asset with no hard, dated binary catalyst (PDUFA, pivotal readout, or AdComm) scheduled in the next ~12 months. The next catalyst is the planned Phase 3 trial initiation in 2027, which is a soft timeline event, not a binary outcome. The drug is one of several pipeline programs at a commercial-stage company whose main near-term value driver is the relacorilant PDUFA on December 17, 2026.
Actionable Insight MIXED

Dazucorilant's next catalyst is the planned Phase 3 trial initiation, expected in 2027 per the Q3 2026 earnings call. There is no PDUFA or binary readout date on the calendar for this drug within the next 12 months. The main near-term value driver for Corcept is the relacorilant PDUFA for Cushing's syndrome on December 17, 2026, not dazucorilant. Investors should watch for Phase 3 trial design details and enrollment timelines as the next meaningful derisking event.

Price Chart

Loading chart...

Executive Summary

Dazucorilant (CORT-113176) is an oral, brain-penetrant selective glucocorticoid receptor modulator being developed by Corcept Therapeutics (NASDAQ: CORT) primarily for amyotrophic lateral sclerosis (ALS). In the Phase 2 DAZALS study (249 patients), the drug failed its primary endpoint of slowing disease progression but showed a striking 87% reduction in risk of death at two years for the 300 mg dose versus placebo. The FDA has granted Fast Track Designation. Corcept plans to initiate a pivotal Phase 3 trial in 2027, per the company's Q3 2026 earnings call. Dazucorilant is an early-stage pipeline asset at a profitable commercial-stage company; the survival signal is compelling but unconfirmed, and there is no near-term binary catalyst for this drug specifically. The stock's main near-term catalyst is the relacorilant PDUFA for Cushing's syndrome on December 17, 2026.

How It Works

Dazucorilant is an oral pill that blocks the effects of cortisol, a stress hormone, by binding to its receptor (the glucocorticoid receptor). In neurodegenerative diseases like ALS, elevated cortisol is thought to contribute to nerve cell damage and inflammation. By modulating cortisol activity, dazucorilant aims to reduce neuroinflammation and slow disease progression. It is designed to cross into the brain (brain-penetrant), which is important for treating neurological conditions.

Trial Status

The Phase 2 DAZALS study (NCT05407324) randomized 249 ALS patients to 150 mg, 300 mg, or placebo daily for 24 weeks. The primary endpoint (change in ALSFRS-R score) was not met. However, a secondary analysis showed the 300 mg dose reduced the risk of death by 87% over two years versus placebo. An open-label extension is ongoing. Corcept plans to initiate a Phase 3 trial in 2027, with overall survival as the primary endpoint.

The Two-Sided Case

▲ Bull Case5
Phase 2 data showed an 87% reduction in risk of death at two years for the 300 mg dose versus placebo, a large survival signal in a disease with few treatment options (source: Corcept press release Apr 30, 2026).
FDA granted Fast Track Designation, which can accelerate development and review (source: Corcept press release Dec 11, 2024).
Corcept is a well-capitalized commercial-stage company with $662.3M in cash and $340.5M in quarterly revenue (+64% YoY), eliminating financing risk for the Phase 3 program (source: Q3 2026 earnings 8-K filed Nov 3, 2026).
The company has deep expertise in cortisol modulation with multiple approved products (Korlym, Lifyorli), and dazucorilant is a brain-penetrant selective GR modulator designed for CNS indications.
Analyst consensus is bullish on CORT (10 Buy/Strong Buy, 1 Hold, 1 Sell) with a mean price target of $141, implying ~78% upside from the $79.22 close.
▼ Bear Case5
Phase 2 DAZALS study failed its primary endpoint of slowing ALS disease progression (ALSFRS-R decline), a significant red flag (source: Corcept press release Dec 11, 2024).
The survival benefit was a secondary endpoint; ALS has a history of promising Phase 2 survival signals failing to replicate in larger Phase 3 trials.
Phase 3 has not yet started (planned for 2027), meaning pivotal data are likely 3-5 years away, with no near-term binary catalyst for this drug.
ALS is a notoriously difficult indication with high Phase 3 failure rates; approved competitors include Rilutek, Radicava, RELYVRIO, and QALSODY.
Insider selling at CORT has been heavy in recent months (Maduck, Wilson, Vieira sold shares in Oct-Nov 2026), though most sales were under 10b5-1 plans.

Upcoming Catalysts

  • Phase 3 trial initiation expected in 2027 (no specific date announced)
  • Any FDA feedback on Phase 3 trial design following Fast Track interactions

Source Filing

The SecBot filing or press-release report that triggered this drug report:

CORCEPT THERAPEUTICS INC 8-K CORT ·Originating report

Sources · 10

Hover a chip for the title
1 ir.corcept.com2 ir.corcept.com3 ir.corcept.com4 benzinga.com5 biospace.com6 adisinsight.springer.com7 en.wikipedia.org8 marketbeat.com9 alsnewstoday.com10 sec.gov